BOSTON–Syntis Bio Inc. has reported new clinical trial results showing that its experimental oral obesity treatment, SYNT-101, produced weight loss and changes in appetite-regulating hormones similar to those associated with gastric bypass surgery, while demonstrating a tolerability profile comparable to placebo.
The findings from the Phase 1/1b SYNTIETY-1 trial were presented at The Obesity Society’s 44th Annual Meeting during ObesityWeek 2026. The company presented two scientific posters, including a late-breaking presentation detailing the treatment’s effects on weight reduction, gut hormones and gastrointestinal safety.
SYNT-101 is an investigational once-daily tablet designed to temporarily coat the upper small intestine, redirecting nutrients farther along the digestive tract. This process is intended to stimulate the body’s natural production of hormones that regulate appetite and metabolism.
Unlike injectable GLP-1 medications, which act directly on specific hormone receptors, SYNT-101 is designed to work within the gastrointestinal tract without entering the bloodstream.
The study enrolled 55 participants across two phases. The single ascending dose portion involved 32 healthy adults, while the multiple ascending dose portion evaluated 23 adults with obesity who received daily treatment for 28 days.
After 28 days, participants receiving SYNT-101 demonstrated placebo-adjusted weight reductions of 1.26%, 0.46% and 2.30% across the three dose groups. The pooled placebo-adjusted reduction was 1.37%, which the company reported as statistically significant.
The highest-dose group, receiving 2,571 milligrams daily, experienced the greatest weight reduction during the study.
Researchers also observed changes in several hormones involved in appetite regulation. At Day 28, levels of peptide YY (PYY), a hormone associated with feelings of fullness, increased 5.1-fold, while glucagon-like peptide-1 (GLP-1) increased 2.3-fold compared with pretreatment levels.
Ghrelin, a hormone that stimulates hunger, declined by 37%, while insulin levels remained unchanged.
The highest-dose group also demonstrated the strongest PYY response, with levels increasing 8.7-fold. Researchers described the relationship between hormone activity and weight reduction as an exploratory finding that could help guide future dosing studies.
“SYNT-101 takes a fundamentally different approach from today’s incretin obesity medicines,” said David Rosenbaum, Ph.D., Chief Development Officer of Syntis Bio. “SYNT-101 is designed to remain within the gastrointestinal tract and not to be systemically absorbed. Rather than stimulating a receptor, SYNT-101 acts through nutrient redirection, forming a temporary lining in the upper small intestine that shifts nutrients further down the gut, where they trigger the body’s own satiety hormones with each meal. The relationship between hormone response and weight loss observed across SYNTIETY-1 cohorts provides a clear basis for dose selection as we design a Phase 2 study to characterize dose response and the trajectory of weight loss over a longer treatment period.”
The treatment also demonstrated favorable preliminary safety findings. No participants discontinued treatment during the trial, and gastrointestinal adverse events occurred at similar rates among those receiving SYNT-101 and placebo.
Treatment-related gastrointestinal side effects were reported in 35% of participants receiving SYNT-101, compared with 33% of those receiving placebo. Researchers observed no clear relationship between dosage and gastrointestinal side effects, and no treatment-related vomiting was reported.
The findings suggest that SYNT-101 could offer a different approach to obesity treatment by stimulating several naturally occurring hormones rather than targeting a single receptor.
Rahul Dhanda, CEO of Syntis Bio, said the company sees potential for the treatment among patients who struggle with existing weight-loss medications or are unable to access other interventions.
“SYNT-101 is positioned to address segments of the obesity market that current approaches to weight management leave largely unserved. Among incretin treated patients, many do not achieve target weight loss or discontinue therapy due to tolerability and cost, and while bariatric surgery remains the most effective and durable intervention, fewer than 1% of eligible patients undergo the procedure each year,” said Dhanda. “With SYNT-101, we have the unique opportunity to deliver the same meal-driven hormonal biology of surgery in a once-daily, oral tablet, as opposed to the constant exposure created by injectables. It represents a distinct therapeutic approach rather than an alternative incretin, which we believe positions it as a potential monotherapy, a complement to GLP-1 therapy and a maintenance option following GLP-1 discontinuation.”
The company is also investigating whether its intestinal coating technology could be used to improve the absorption of oral peptide medications and support treatments for rare pediatric metabolic disorders.
Dhanda said the trial provides early clinical evidence supporting the broader technology platform.
“SYNTIETY-1 also provides the first clinical validation of the broader SYNT platform. The same transient lining underpins our programs to enhance the oral bioavailability of peptide therapeutics and to retain therapeutic enzymes in the gut for rare pediatric metabolic diseases, extending this safety foundation across our pipeline.”
Although the early results indicate potential benefits, the trial primarily evaluated safety and tolerability, and its relatively small size and short treatment period mean additional research is needed to establish the drug’s effectiveness and longer-term safety.
Syntis Bio plans to begin a Phase 2 clinical trial of SYNT-101 in 2027 to further evaluate weight loss, dosing and treatment outcomes over a longer period.


